BioVeda China Fund (BVCF) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, and Bejing
Employees: 11-50
Investment Type: Venture Capital
Persons 3
Date | First Name | Last Name | Title | Location | |||
- | Huacheng | Wei | Adviser | - | - | - | |
- | Bing | Zhuo | Adviser | - | - | - | |
- | Yunlong | Huang | Adviser | - | - | - |
Mentions in press and media 6
Date | Title | Description |
07.05.2021 | Oculis closes US$57 million Series C financing | |
07.05.2021 | Oculis closes US$57 million Series C financing | The oversubscribed round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Cap... |
18.04.2016 | Lifescience-focussed BioVeda China Fund seeks $400m for fourth vehicle | Premium China-based investment firm with a focus on life sciences BioVeda China Fund (BVCF) is working on launching a $400 million fund, according to China Money Network quoting unnamed sources. Continue reading this story with a subscripti... |
09.01.2015 | DiaCarta Raises $8M in Series A Financing | DiaCarta, Inc., a Hayward, CA-based biotechnology company, raised $8m in Series A financing. Shanghai-based BioVeda China Fund made the investment. The company intends to use the funds to expand its product portfolio and support global comm... |
06.02.2014 | Jaguar Animal Health Raises $2M | Jaguar Animal Health, Inc., a San Francisco, CA-based company focused on the development and commercialization of health solutions for the global veterinary marketplace from plants used traditionally in rain forest areas, raised $2m in a Se... |
22.08.2013 | MicuRx Pharmaceuticals Raises $25M in Series B Financing | MicuRx Pharmaceuticals, Inc., a Hayward, CA-based biopharmaceutical company developing innovative antibiotics, raised $25m in Series B financing. The round was led by BVCF, with participation from existing investors Morningside Group and De... |